Additionally, the 36-month beta value for OLMA is 2.06. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for OLMA is 42.88M and currently, short sellers hold a 23.24% ratio of that float. The average trading volume of OLMA on January 07, 2025 was 750.47K shares.
OLMA) stock’s latest price update
Olema Pharmaceuticals Inc (NASDAQ: OLMA)’s stock price has dropped by -4.00 in relation to previous closing price of 5.50. Nevertheless, the company has seen a loss of -5.88% in its stock price over the last five trading days. globenewswire.com reported 2025-01-03 that SAN FRANCISCO, Jan. 03, 2025 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to three new employees to purchase an aggregate of 26,200 shares of the Company’s common stock, effective as of January 2, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company’s 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
OLMA’s Market Performance
Olema Pharmaceuticals Inc (OLMA) has experienced a -5.88% fall in stock performance for the past week, with a -48.64% drop in the past month, and a -53.40% drop in the past quarter. The volatility ratio for the week is 9.64%, and the volatility levels for the past 30 days are at 10.31% for OLMA. The simple moving average for the past 20 days is -18.80% for OLMA’s stock, with a -52.40% simple moving average for the past 200 days.
Analysts’ Opinion of OLMA
Many brokerage firms have already submitted their reports for OLMA stocks, with Goldman repeating the rating for OLMA by listing it as a “Buy.” The predicted price for OLMA in the upcoming period, according to Goldman is $24 based on the research report published on April 02, 2024 of the previous year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see OLMA reach a price target of $20. The rating they have provided for OLMA stocks is “Buy” according to the report published on January 30th, 2024.
Oppenheimer gave a rating of “Outperform” to OLMA, setting the target price at $21 in the report published on July 21st of the previous year.
OLMA Trading at -41.13% from the 50-Day Moving Average
After a stumble in the market that brought OLMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.52% of loss for the given period.
Volatility was left at 10.31%, however, over the last 30 days, the volatility rate increased by 9.64%, as shares sank -49.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -54.52% lower at present.
During the last 5 trading sessions, OLMA fell by -4.99%, which changed the moving average for the period of 200-days by -53.85% in comparison to the 20-day moving average, which settled at $6.51. In addition, Olema Pharmaceuticals Inc saw -9.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OLMA starting from Graham G. Walmsley, who sale 700,761 shares at the price of $6.75 back on Dec 17 ’24. After this action, Graham G. Walmsley now owns 0 shares of Olema Pharmaceuticals Inc, valued at $4,730,137 using the latest closing price.
Logos Opportunities Fund I LP, the Affiliate of Olema Pharmaceuticals Inc, proposed sale 700,761 shares at $6.75 during a trade that took place back on Dec 13 ’24, which means that Logos Opportunities Fund I LP is holding shares at $4,730,137 based on the most recent closing price.
Stock Fundamentals for OLMA
Current profitability levels for the company are sitting at:
- -72.14 for the present operating margin
- 0.86 for the gross margin
The net margin for Olema Pharmaceuticals Inc stands at -65.12. The total capital return value is set at -0.68. Equity return is now at value -51.76, with -46.92 for asset returns.
Currently, EBITDA for the company is -104.58 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of 143.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.10.
Conclusion
In conclusion, Olema Pharmaceuticals Inc (OLMA) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
